Pyxis OncologyPYXS
PYXS
About: Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.
Employees: 54
0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
625% more call options, than puts
Call options by funds: $2.02M | Put options by funds: $279K
109% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 11
56% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 18
15% more funds holding
Funds holding: 80 [Q2] → 92 (+12) [Q3]
10% more capital invested
Capital invested by funds: $93.3M [Q2] → $102M (+$8.98M) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q2] → 2 (+0) [Q3]
0.98% less ownership
Funds ownership: 47.91% [Q2] → 46.93% (-0.98%) [Q3]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$5
196%
upside
Avg. target
$8.67
413%
upside
High target
$13
669%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Swayampakula Ramakanth 30% 1-year accuracy 52 / 173 met price target | 196%upside $5 | Buy Reiterated | 20 Dec 2024 |
RBC Capital Leonid Timashev 43% 1-year accuracy 19 / 44 met price target | 373%upside $8 | Outperform Reiterated | 20 Dec 2024 |
Stephens & Co. Sudan Loganathan 0 / 0 met price target | 669%upside $13 | Overweight Initiated | 8 Nov 2024 |
Financial journalist opinion
Based on 3 articles about PYXS published over the past 30 days
Neutral
GlobeNewsWire
1 day ago
Pyxis Oncology Announces Portfolio Prioritization, Focusing Resources on its Lead Clinical Program, PYX-201
- The Company will focus resources on advancing its lead asset, PYX-201 - PYX-201 is a novel first-in-concept antibody-drug conjugate (ADC) where significant RECIST responses were seen in head and neck squamous cell carcinoma (HNSCC) with additional potential in other solid tumors - Current cash runway expected to fund development into 2H 2026 BOSTON, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced a portfolio prioritization, focusing resources on advancing its lead clinical program, PYX-201, a first-in-concept antibody-drug conjugate (ADC) with a microtubule inhibitor (optimized auristatin) payload that uniquely targets Extradomain-B Fibronectin (EDB+FN), a non-cellular structural component within the tumor extracellular matrix. In November 2024, Pyxis Oncology reported positive preliminary data from the ongoing Phase 1 dose-escalation study of PYX-201, evaluating its safety and efficacy in multiple solid tumor types.
Positive
Seeking Alpha
2 weeks ago
Pyxis Oncology: Speculative Buy Opportunity With Multiple Catalysts Ahead
Pyxis Oncology's lead candidate, PYX-201, showed promising response rates in Phase 1 trials but raised safety concerns due to a patient's death. The company's valuation appears deeply discounted, with a P/B ratio of 0.7 compared to a sector median of 2.4, reflecting market pessimism. PYX-201's ongoing trials and upcoming catalysts in 2025-2026 are crucial for addressing safety concerns and demonstrating efficacy across multiple cancer types.
Negative
Benzinga
4 weeks ago
Pyxis Oncology's Cancer Drug Progress Stirs Analyst Concerns
On Wednesday, Pyxis Oncology, Inc. PYXS released preliminary data from the ongoing Phase 1 clinical dose escalation study evaluating PYX-201 in multiple solid tumors.
Neutral
GlobeNewsWire
1 month ago
Pyxis Oncology Announces Favorable Preliminary PYX-201 Clinical Phase 1 Part 1 Data
— PYX-201 achieved a confirmed 50% ORR by RECIST 1.1 including one Complete Response and 100% Disease Control Rate in six heavily pretreated HNSCC patients, supporting differentiated mono and front-line combo therapy expansion trials to begin dosing 1Q25
Positive
Benzinga
1 month ago
Pyxis Oncology's Cancer Drug Platform Shows Potential, Analyst Sees Over 190% Upside
Stephens has initiated coverage on Pyxis Oncology Inc PYXS, highlighting the company's technology platform aimed at developing next-gen antibody-drug conjugates (ADCs) with enhanced potency, stability, and tolerability.
Neutral
PRNewsWire
2 months ago
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Pyxis Oncology, Inc. (NASDAQ:PYXS)
NEW YORK , Sept. 25, 2024 /PRNewswire/ -- Levi & Korsinsky announces that it has commenced an investigation of Pyxis Oncology, Inc. (NASDAQ:PYXS) concerning possible breaches of fiduciary duty.
Neutral
Seeking Alpha
3 months ago
Moment Of Truth Approaches For Pyxis Oncology
Pyxis Oncology is an antibody and antibody-drug conjugate developer with initial results from two clinical trials ahead in 2024. Data from a phase 1 study of PYX-201, an ADC targeting extra domain B of fibronectin, in multiple tumor types, are expected in fall 2024. Data from a phase 1 study of PYX-106, an anti-Siglec-15 antibody, in multiple tumor types, are expected by year-end 2024.
Neutral
GlobeNewsWire
3 months ago
Pyxis Oncology to Participate in Two Upcoming Investor Conferences
BOSTON, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today announced that Lara S. Sullivan, M.D., President and Chief Executive Officer, will participate in fireside chats and members of management will participate in one-on-one meetings at the following two upcoming investor conferences:
Neutral
GlobeNewsWire
4 months ago
Pyxis Oncology Provides Corporate Update and Reports Financial Results for Second Quarter 2024
- Preliminary data from the Phase 1 trial of PYX-201 remains on track to be announced in the fall of 2024 - Preliminary data from the Phase 1 trial of PYX-106 is expected to be reported by year-end 2024 - Expected cash runway into 2H 2026 BOSTON, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today reported financial results for the second quarter ended June 30, 2024, and provided a corporate update. The Company ended the second quarter of 2024 with $157.2 million in cash, cash equivalents, restricted cash and short-term investments, which is expected to provide cash runway into the second half of 2026 and enable the Company to fund the next phase of PYX-201 clinical development, which the Company plans to announce in the fall of 2024.
Neutral
GlobeNewsWire
4 months ago
Pyxis Oncology to Participate in the BTIG Virtual Biotechnology Conference
BOSTON, July 29, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, announced today that Lara S. Sullivan, M.D., President and Chief Executive Officer, and members of management will participate in one-on-one meetings at the BTIG Virtual Biotechnology Conference being held August 5-6, 2024.
Charts implemented using Lightweight Charts™